Atyr Pharma Inc
Atyr Pharma Inc (ATYR) Historical Volatility
ATYR's 30 day historical volatility is 105.30%, in the 85th percentile of readings over the past year. This is a high percentile, meaning Atyr Pharma Inc shares have swung far more than usual. ATYR's 30 day implied volatility sits at 631.68%, with an IV Rank of 89.29%, leaving IV 526.38 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 19, 2026.
Read more
Tracking ATYR historical volatility helps you see how much Atyr Pharma Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ATYR's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ATYR 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ATYR's 30 day historical volatility, or ATYR HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ATYR's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 19, 2026
As of Nov 19, 2026
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →